



Standard Test Method for Evaluation of Cytotoxicity of Nanoparticulate Materials in Porcine Kidney Cells and Human Hepatocarcinoma Cells¹

This standard is issued under the fixed designation E2526; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This test method provides a methodology to assess the cytotoxicity of suspensions of nanoparticulate materials in porcine proximal tubule cells (LLC-PK1) and human hepatocarcinoma cells (Hep G2) which represents potential target organs following systemic administration

1.2 This test method is part of the *in vitro* preclinical characterization cascade.

1.3 This test method consists of a protocol utilizing two methods for estimation of cytotoxicity, 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) reduction and lactate dehydrogenase (LDH) release.

1.4 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.5 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.*

2. Referenced Documents

2.1 ASTM Standards:²

F813 Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices

F895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity

F1877 Practice for Characterization of Particles

F1903 Practice for Testing For Biological Responses to Particles *In Vitro*

¹ This test method is under the jurisdiction of ASTM Committee E56 on Nanotechnology and is the direct responsibility of Subcommittee E56.03 on Environment, Health, and Safety.

Current edition approved Sept. 1, 2013. Published September 2013. Originally approved in 2008. Last previous edition approved in 2008 as E2526 – 08. DOI: 10.1520/E2526-08R13.

² For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

2.2 ISO Standard:³

ISO 10993-5 Biological Evaluation of Medical Devices: Part 5 Tests for *in vitro* Cytotoxicity

3. Terminology

3.1 Abbreviations:

3.1.1 **APAP**—acetaminophen- positive control

3.1.2 **DMSO**—dimethyl sulfoxide

3.1.3 **DMEM**—Dulbecco's modified eagles media

3.1.4 **Hep G2**—human hepatocarcinoma cells

3.1.5 **LDH**—lactic dehydrogenase

3.1.6 **LLC-PK1**—porcine proximal tubule cells

3.1.7 **LPS**—lipopolysacchride, bacterial endotoxin

3.1.8 **MTT**—3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide

3.1.9 **Physiologic solution**—isotonic with a pH 7.2 ± 0.2

4. Summary of Test Method

4.1 Nanoparticulate test materials in suspension in cell culture media and appropriate controls are added to cell cultures. The release of LDH indicates membrane damage and the diminution of MTT reduction indicates loss of cell viability. These are quantitative indicators of cytotoxicity. Aseptic procedures are required.

5. Significance and Use

5.1 Assessing the propensity of a nanomaterial to cause cytotoxicity to the cells of a target organ can assist in preclinical development.

5.2 The standard historical cytotoxicity testing of materials and extracts of materials has used fibroblasts and is well documented in Practice **F813**, Test Method **F895**, and ISO 10993-5. The use of macrophages and micron size particles has also provided information on cytotoxicity and stimulation using Practice **F1903**.

³ Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, <http://www.ansi.org>.

5.3 This test method adds to the cytotoxicity test protocols by using target organ cells. Two quantitative assays measuring LDH leakage and MTT reduction are used to estimate cytotoxicity.

5.4 This test method may not be predictive of events occurring in all types of nanomaterial applications and the user is cautioned to consider the appropriateness of the test for various types of nanomaterial applications. This procedure should only be used to compare the cytotoxicity of a series of related nanomaterials. Meaningful comparison of unrelated nanomaterials is not possible without additional characterization of physicochemical properties of each individual nanomaterial in the assay matrix.

6. Reagents and Materials

6.1 *Purity of Reagents*—Reagent grade chemicals shall be used in all tests. Unless otherwise indicated, it is intended that all reagents conform to the specifications of the Committee on Analytical Reagents of the American Chemical Society where such specifications are available.⁴ Other grades may be used, provided it is first ascertained that the reagent is of sufficiently high purity to permit its use without lessening the accuracy of the determination.

6.2 Reagents and supplies (aseptic procedures are needed and care should be taken to use sterile reagents and supplies as necessary).

6.2.1 MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide).

6.2.2 Acetaminophen.

6.2.3 Dimethyl sulfoxide.

6.2.4 Glycine.

6.2.5 Sodium Chloride.

6.2.6 Medium 199 Cell Culture Media.

6.2.7 Triton X 100.

6.2.8 LDH-Cytotoxicity Assay Kit (Biovision Cat. # K311-400 was used in developing this test method)*.

6.2.9 96 well flat bottom cell culture plates.

6.2.10 RPMI 1640.

6.2.11 L-glutamine.

6.2.12 Fetal bovine serum (FBS).

6.3 *Cell Lines:*

6.3.1 LLC- PK1 (porcine proximal tubule cell) (ATCC#CL-101)*.

6.3.2 Hep G2 (human hepatocarcinoma)(ATCC # HB-8065)*.

6.4 *Equipment:*

6.4.1 Plate reader.

6.4.2 Plate Centrifuge set at 700-800 g.

6.4.3 Cell Culture Microscope.

NOTE 1—Commercial sources are indicated for informational purposes

⁴ *Reagent Chemicals, American Chemical Society Specifications*, American Chemical Society, Washington, DC. For Suggestions on the testing of reagents not listed by the American Chemical Society, see *Analar Standards for Laboratory Chemicals*, BDH Ltd., Poole, Dorset, U.K., and the *United States Pharmacopeia and National Formulary*, U.S. Pharmacopeial Convention, Inc. (USPC), Rockville, MD.

only to aid laboratories initiating these test procedures. This does not indicate endorsement by ASTM. Other equivalent sources may be available.

7. Experimental Procedure

7.1 Aseptic precautions are required.

7.2 *Positive Control Preparation:*

7.2.1 LLC-PK1 Acetaminophen (APAP) positive control: 25 mM APAP in M199 cell culture media.

7.2.2 Hepatocyte Acetaminophen (APAP) positive control: 20 mM APAP in RPMI 1640 cell culture media.

7.2.3 Triton X100 is diluted to 1 % in cell culture medium. This is the positive control for the LDH assay.

7.3 *MTT Assay Reagents:*

7.3.1 MTT solution-5mg/mL MTT in PBS, store for up to one month at 4°C in the dark.

7.3.2 Glycine Buffer-0.1M glycine (MW 75.07), 0.1 M NaCl (MW 58.44), pH 10.5, store at room temperature.

7.4 *Biovision LDH-Cytotoxicity Assay Kit Reagents:*

7.4.1 Reconstitute catalyst in 1 mL dH₂O for 10 min and vortex (stable for 2 weeks at 4°C).

7.4.2 Reaction mixture (for one 96-well plate): Add 250 mL of reconstituted, catalyst solution to 11.25 mL of dye solution (stable for 2 weeks at 4°C).

7.4.3 For other LDH Cytotoxicity assay kits, follow their instructions.

7.5 *Cell Culture:*

7.5.1 *LLC-PK1 Cell Preparation:*

7.5.1.1 Harvest cells from flasks prepared from cryopreserved cells according to the instructions from the supplier (limit passages to 20). An example of the appearance of the cells is in Fig. 1.

7.5.1.2 Count cell concentration using a Coulter type counter or hemocytometer.

7.5.1.3 Dilute cells to a density of 2.5×10^5 cells/mol in M199 (3 % FBS) cell culture media.

7.5.1.4 4 Plate 100 μ L cells/well as per plate format described in Fig. 3 for 4 plates (time zero, 6 hour sample exposure, 24 hour sample exposure, 48 hour sample exposure). The format indicates no cells in rows D&E and they serve as particle controls. Each plate accommodates two samples (Rows A-C and F-H). Each nanoparticulate material is tested at 9 dilutions. Column 11 receives the positive control and column 12 receives Triton X 100.

7.5.1.5 Incubate plates for 24 hours at 5 % CO₂, 37°C and 95 % humidity (cells should be approximately 80 % confluent).

7.5.2 *Hep G2 Cell Preparation:*

7.5.2.1 Harvest cells from flasks prepared from cryopreserved cells according to the instructions from the supplier. (limit passages to 20). An example of the appearance of the cells is in Fig. 2.

7.5.2.2 Count cell concentration using a Coulter type counter or hemocytometer.

7.5.2.3 Dilute cells to a density of 5.0×10^5 cells/mol in RPMI 1640 (2 mM L-glutamine, 10 % FBS) cell culture media.

7.5.2.4 Plate 100 μ L cells/well as per plate format described in Fig. 3 for 4 plates (time zero, 6 hour sample exposure, 24